Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
272 studies found for:    "Herpes Zoster" [DISEASE]
Show Display Options
Rank Status Study
21 Completed Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
22 Completed Study to Evaluate Efficacy, Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 70 Years and Older
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine GSK1437173A;   Biological: Placebo
23 Completed Study to Assess the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) When Co-administered With GSK Biologicals' Diphtheria, Tetanus and Pertussis Vaccine (Boostrix®) in Adults Aged 50 Years and Older
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: Boostrix
24 Active, not recruiting Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults 18 Years of Age or Older With Renal Transplant
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster vaccine GSK1437173A;   Drug: Placebo
25 Completed Safety and Immunogenicity Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A When Administered Subcutaneously Intramuscularly in Adults Aged ≥50 Years
Condition: Herpes Zoster
Intervention: Biological: Herpes zoster vaccine GSK1437173A
26 Completed
Has Results
Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Vaccine GSK1437173A When Co-administered With GSK Biologicals' Seasonal Influenza Vaccine GSK2321138A in Adults Aged 50 Years and Older
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster vaccine GSK 1437173A;   Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A
27 Completed A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster
Condition: Herpes Zoster
Intervention: Drug: valacyclovir hydrocholoride
28 Completed Phase III Study of ASP2151 in Herpes Zoster Patients
Condition: Herpes Zoster
Interventions: Drug: ASP2151;   Drug: valaciclovir
29 Completed Use of an Electronic Medical Record in the Primary Care Setting to Improve Herpes Zoster Vaccination Rates
Condition: Herpes Zoster Disease
Intervention: Other: An informational packet regarding shingles and the HZV was sent to patients identified by the EMR
30 Completed
Has Results
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
Condition: Herpes Zoster
Intervention: Other: Choosing to receive the vaccine
31 Recruiting Efficacy of Oral Famciclovir Versus Aciclovir Treatment in Patients With Herpes Zoster
Condition: Herpes Zoster
Interventions: Drug: Famciclovir;   Drug: Aciclovir
32 Completed
Has Results
A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)
Condition: Herpes Zoster
Interventions: Biological: zoster vaccine live (ZOSTAVAX™);   Biological: Comparator: Placebo
33 Active, not recruiting Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds
Conditions: Shingles;   Herpes Zoster
Interventions: Biological: Zostavax;   Biological: HZ/su vaccine;   Biological: Placebo
34 Completed Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years
Conditions: Herpes Zoster;   Herpes Zoster Vaccine
Interventions: Biological: Herpes zoster vaccine GSK1437173A;   Biological: Placebo
35 Completed A Study of FV-100 Versus Valacyclovir in Patients With Herpes Zoster
Conditions: Herpes Zoster;   Shingles
Interventions: Drug: valacyclovir;   Drug: FV-100;   Drug: Valacyclovir placebo;   Drug: FV-100 placebo
36 Recruiting A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults
Condition: Herpes Zoster
Intervention: Biological: Herpes Zoster Vaccine GSK1437173A
37 Active, not recruiting Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
Condition: Herpes Zoster
Intervention: Other: Data collection
38 Completed Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects
Condition: Herpes Zoster
Interventions: Biological: Herpes Zoster Vaccine 1437173A;   Biological: Placebo
39 Completed Study to Estimate the Burden of Herpes Zoster and Postherpetic Neuralgia in Spain
Condition: Herpes Zoster
Intervention: Other: Data collection
40 Recruiting Study to Estimate the Burden of Herpes Zoster (HZ) and Post-herpetic Neuralgia (PHN) in Italy
Condition: Herpes Zoster
Intervention: Other: Data collection

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.